Noa Schwartz, MD, MS, is a clinician and researcher with a special interest and expertise in Systemic Lupus Erythematosus, and is the Director of the Montefiore-Einstein Institute for Lupus Care and Research.

After obtaining her M.D. from Hebrew University – Hadassah Medical School in Jerusalem, Israel, Dr. Schwartz went on to residency in internal medicine at Montefiore Medical Center (Bronx, NY), where she also served as Chief Resident. She then completed her rheumatology fellowship at the Hospital for Special Surgery (New York, NY). In addition to her medical education, Dr. Schwartz obtained an M.S. with distinction in clinical research methodology at the Albert Einstein College of Medicine Clinical Research Training Program.

Dr. Schwartz’s research interests are in studying Systemic Lupus Erythematosus, with specific focus on kidney, skin and neuropsychiatric manifestations. She studies this complex disease from a translational perspective by investigating potential biomarkers, ranging from cytokines to single-nucleotide polymorphisms, to basic research into the lymphatic system and its role in lupus photosensitivity. She also serves as a principal investigator on lupus-related clinical trials. In addition to her investigational activities, Dr. Schwartz has published clinical review papers in prestigious journals, as well as authored book chapters, and educational lectures.

Schwartz N, Su L, Burkly LC, Mackay M, Aranow C, Kollaros M, Michaelson JS, Rovin B, Putterman C. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006; 27:242-50.

Pitashny M, Schwartz N, Putterman C. Managing lupus: current and developing therapies. J Musculoskel Med 2006; 23:219-36.

Pitashny M, Schwartz N, Qing X, Hojaili B, Aranow C, Mackay M, Putterman C. Urinary Lipocalin-2 as a potential biomarker for human lupus nephritis. Arthritis Rheum 2007; 56:1894-903.

Wu T, Xie C, Wang HW, Zhou XJ, Schwartz N, Calixto S, Mackay M, Aranow C, Putterman C, Mohan C. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol 2007; 179:7166-75.

Zhao Z, Burkly LC, Campbell S, Schwartz N, Molano A, Choudhury A, Eisenberg RA, Michaelson JS, Putterman C. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 2007; 179:7949-58.

Schwartz N, Michaelson JS, Putterman C. Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. Ann NY Acad Sci 2007; 1109:265-74.

Schwartz N, Rubinstein T, Burkly LC, Collins CE, Blanco I, Su L, Hojaili B, Mackay M, Aranow C, Stohl W, Rovin BH, Michaelson JS, Putterman C. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009; 11:R143.

Rubinstein T, Pitashny M, Levine B, Schwartz N, Schwartzman J, Weinstein E, Pego-Regiosa JM, Lu TT, Isenberg D, Rahman A, Putterman C. Urinary neutrophil gelatinase associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology 2010; 49:960-71.

Schwartz N, Mitnick HJ, Nowatzky J. Headaches related to rheumatologic disease. Curr Pain Headache Rep 2013; 17:381.

Schwartz N, Putterman C, ‘Nephritogenic antibodies in systemic lupus erythematosus’, in IR Mackay, NR Rose (ed.), Encyclopedia of Medical Immunology – Autoimmune Diseases, Springer Science+Business Media, New York 2014, DOI 10.1007/978-0-387-84828-0.

Schwartz N, Goilav B, Putterman C. The pathogenesis, diagnosis and treatment of lupus nephritis. Curr Opin Rheumatol 2014; 26:502-509.

Schwartz N, Stock AD, Putterman C. Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat Rev Rheumatol 2019; 15: 137-52. DOI 10.1038/s41584-018-0156-8.

Schwartz N, Chalasani MLS, Li TM, Feng Z, Shipman WD, Lu TT. Lymphatic function in autoimmune diseases. Front Immunol 2019; 10:519. DOI: 10.3389/fimmu.2019.00519

Oláh C, Schwartz N, Denton C, Kardos Z, Putterman C, Szekanecz Z. Cognitive dysfunction in autoimmune rheumatic diseases. Arthritis Res Ther 2020; 22:78. DOI: 10.1186/s13075-020-02180-5.

Iacobas D, Wen J, Iacobas S, Schwartz N*, Putterman C* (co-senior authors). Remodeling of neurotransmission, chemokine, and PI3K-AKT signaling genomic fabrics in neuropsychiatric systemic lupus erythematosus. Genes (Basel) 2021; 12:251. doi: 10.3390/genes12020251.

Iacobas DA, Wen J, Iacobas S, Putterman C, Schwartz N. TWEAKing the hippocampus: the effects of TWEAK on the genomic fabric of the hippocampus in a neuropsychiatric lupus mouse model. Genes (Basel) 2021; 12: 1172. doi: 10.3390/genes12081172.

Kataru RP, Baik JE, Park HJ, Ly CL, Shin J, Schwartz N, Lu TT, Ortega S, Mehrara BJ. Lymphatic-specific intracellular modulation of receptor tyrosine kinase signaling improves lymphatic growth and funciton. Sci Signal 2021; 14(695):eabc0836. doi 10.1126/scisignal.abc0836.